Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Dismisses Lawsuit against PacBio, Former Employees


By Julia Karow

This story was originally published March 3.

A month after suing Pacific Biosciences and several former employees for unlawfully recruiting its workers and disclosing confidential information, Affymetrix dropped the suit in December.

According to a document filed with the Santa Clara County Superior Court of California, Affymetrix asked the court to dismiss the lawsuit on Dec. 2, 2010. The company provided no explanation in the filing for why it decided to drop the action.

Rick Runkel, Affy's chief legal counsel and executive vice president, said in a statement that the company had settled its claims against PacBio but declined to comment on the terms of the settlement.

A spokesperson for PacBio told In Sequence that "the matter was resolved by mutual agreement, and involved no financial terms."

Affy filed the suit in early November of last year (IS 11/9/2010), claiming that several former employees that joined PacBio as early as 2009 had violated an agreement with Affy not to recruit other Affymetrix staff for one year after leaving the firm. The suit also alleged that PacBio and the former employees induced other Affy workers to disclose confidential information about the company.

In a filing with the Securities and Exchange Commission last November, PacBio said it believed the complaint "is entirely without merit" and intended to "vigorously" defend itself against Affymetrix' claims. PacBio further noted at the time that it had not been served with a copy of the complaint as of Nov. 29, 2010.

Have topics you'd like to see covered in In Sequence? E-mail the editor at jkarow [at] genomeweb [.] com.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.